rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer’s disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine
Sign Up to like & getrecommendations! Published in 2017 at "Brain Imaging and Behavior"
DOI: 10.1007/s11682-017-9803-y
Abstract: Late-onset Alzheimer’s disease (AD) differs substantially from early-onset AD. In this cross sectional study we investigated brain perfusion changes after 18 months of treatment with cholinesterase inhibitors (ChEIs) donepezil or galantamine. Twenty-five drug-naïve late-onset AD patients… read more here.
Keywords: late onset; cog; alzheimer disease; treatment ... See more keywords
Test-retest reliabilities and minimal detectable changes of 5 versions of the Alzheimer's Disease Assessment Scale-Cognitive Subscale in people with dementia.
Sign Up to like & getrecommendations! Published in 2022 at "Disability and rehabilitation"
DOI: 10.1080/09638288.2022.2060334
Abstract: PURPOSE To compare the test-retest reliability and minimal detectable change (MDC) of the commonly used versions of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) (the ADAS-Cog-11 (11 items), ADAS-Cog-3 (three items), ADAS-Cog-5-Subset (five items), ADAS-Cog-6-Subset… read more here.
Keywords: test retest; subset adas; adas rasch; adas cog ... See more keywords
Questioning the Meaning of a Change on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): Noncomparable Scores and Item-Specific Effects Over Time
Sign Up to like & getrecommendations! Published in 2020 at "Assessment"
DOI: 10.1177/1073191120915273
Abstract: Longitudinal invariance indicates that a construct is measured over time in the same way, and this fundamental scale property is a sine qua non to track change over time using ordinary mean comparisons. The Alzheimer’s… read more here.
Keywords: invariance; alzheimer disease; time; adas cog ... See more keywords
The use of the Hungarian Test Your Memory (TYM-HUN), MMSE, and ADAS-Cog tests for patients with mild cognitive impairment (MCI) in a Hungarian population: a cross-sectional study
Sign Up to like & getrecommendations! Published in 2020 at "BMC Psychiatry"
DOI: 10.1186/s12888-020-02982-6
Abstract: Background Mild cognitive impairment (MCI) often presages the development of Alzheimer’s disease (AD). Accurate and early identification of cognitive impairment will substantially reduce the burden on the family and alleviate the costs for the whole… read more here.
Keywords: cognitive impairment; tym; tym hun; adas cog ... See more keywords
Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s' Perceptions.
Sign Up to like & getrecommendations! Published in 2017 at "Current Alzheimer research"
DOI: 10.2174/1567205014666170417122744
Abstract: BACKGROUND The Alzheimer's Disease Assessment Scale-Cognitive subscale (ADASCog) remains the most widely used test of longitudinal cognitive functioning in Alzheimer's disease (AD) clinical trials. Unlike most neuropsychological tests, the ADAS-Cog source documentation worksheets are not… read more here.
Keywords: optimizing adas; worksheets survey; cog worksheets; alzheimer disease ... See more keywords
Is the Alzheimer's Disease Assessment Scale-Cognitive Subscale useful in screening for mild cognitive impairment and Alzheimer's disease? A systematic review.
Sign Up to like & getrecommendations! Published in 2022 at "Current Alzheimer research"
DOI: 10.2174/1567205019666220404104854
Abstract: BACKGROUND Mild cognitive impairment (MCI) and Alzheimer's disease (AD) are screened to distinguish whether cognitive decline in older adults is attributed to pathological causes rather than normal aging. OBJECTIVE The purpose of this review was… read more here.
Keywords: adas cog; mild cognitive; alzheimer disease; cognitive impairment ... See more keywords
Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Neuroscience"
DOI: 10.3389/fnins.2019.00472
Abstract: To study the impact of donepezil, rivastigmine, galantamine, and memantine on cognitive, functional, behavioral, global changes and adverse effects in patients with mild, moderate and severe Alzheimer’s disease (AD), we screened the literature published before… read more here.
Keywords: galantamine; alzheimer disease; treatment; controlled trials ... See more keywords